• Rationale for the symptomatic therapy of respiratory viral infections in children
Come back

Rationale for the symptomatic therapy of respiratory viral infections in children

SOVREMENNAYA PEDIATRIYA.2019.1(97):117-122; doi 10.15574/SP.2019.97.117

Kryuchko T. O., Kushnereva T. V., Harshman V. P., Kuzmenko N. V.
Ukrainian Medical Stomatological Academy, Poltava, Ukraine

Tonsillopharyngitis (TF) is the most common manifestation of acute respiratory viral infection (ARVI), occupying a leading place among the ENT pathology of childhood. The results of numerous studies indicate the need to avoid the use of antibiotics in acute TF non streptococcal etiology. Unreasonable antibacterial therapy promotes the development of resistance to antibiotics, the occurrence of adverse reactions to drugs, as well as expensive treatment. In the uncomplicated course of acute TF, local symptomatic therapy is indicated which includes anti-inflammatory, analgesic and immune-regulating effects.

Research objective. The aim of our study was to evaluate the effectiveness of the prophylactic course of the drug Erebra in the pre-epidemic period of ARVI and to evaluate the effectiveness of the complex symptomatic treatment of acute TF in children with ARVI.

Materials and methods. 55 children of the control group, school age (6–10 years old) who received Erebra prophylactic course in the pre-epidemic period of ARVI for 2 weeks and 20 children in the comparative group, similar in age, who did not have a preventive course, were examined. Child surveillance was carried out during scheduled visits (once a month) and, moreover, during an ARVI.

Results. The study shows a significant decrease in the frequency of episodes of ARVI in 1.6 times in children of the main group. The absence of pain in the oropharynx on the third day was recorded 2 times more often in the group of patients receiving Erebra as local therapy (p>0.05). Regression of the main symptoms is also likely to occur in the main group of children, according to pharyngoscopy of the oropharynx. Reducing (in 2.5 times) the risk of secondary bacterial complications in children with ARVI, received as a local therapy Erebra in the course of the study. Relatively less volume of symptomatic therapy and less duration of school absenteeism (1.5 times) occurred in children of the main group.

Conclusions. The inclusion of Erebra in the complex symptomatic treatment of acute TF in children minimizes the amount of treatment and reduces the frequency of secondary bacterial complications. The use of a 2-week prophylactic course in the pre-epidemic season reduces the risk of recurrent respiratory infections.

Key words: acute respiratory viral infection, acute tonsillopharyngitis, children, symptomatic treatment, Erebra.


1. Bortnikova VV. (2011). Eksperimentalnoe izuchenie bezopasnosti giporamina — novogo fitopreparata protivovirusnogo deystviya. Biomeditsina. 3: 106—108.

2. Ershova IB. (2014). Effektivnost giporamina (erebra) v lechenii i profilaktike virusnyih zabolevaniy u detey. Zdorove rebenka. 8(59): 55—58.

3. Kramarev SA, Vigovskaya OV. (2016). Innovations in the treatment and prevention of acute respiratory viral infections in children. Sovremennaya pediatriya. 1(73): 75—81.

4. Kryuchko TA, Kushnereva TV, Ostapenko VP, Kolenko IA. (2014). Problematic issues of outpatient management of children with acute respiratory viral infections. Sovremennaya pediatriya. 8(64): 65—69. doi 10.15574/SP.2014.64.65

5. Rubleva OV. (2012). K voprosu o terapii i profilaktike virusnyih infektsiy Poliklinika. 4: 108—110.

6. Soldatskiy YuL, Onufrieva EK, Gasparyan SF i dr. (2014). Vyibor optimalnogo sredstva dlya mestnogo lecheniya faringita u detey. Zdorove rebenka. 1(52): 105—109.

7. Harold K Simon. Pediatric Pharyngitis Treatment & Management https://emedicine.medscape.com/article/967384-treatment.

8. Krejcarov J, Strakov E, Such P. Sea buckthorn (Hippophae rhamnoides L.) as a potential source of nutraceutics and its therapeutic possibilities — a review. (2015). Acta Vet. Brno. 84: 257—268. https://doi.org/10.2754/avb201584030257.

9. Kuduban O, Mazlumoglu MR et al. (2016, Sep-Oct). The effect of hippophae rhamnoides extract on oral mucositis induced in rats with methotrexate. J Appl Oral Sci. 24(5): 423—430. https://doi.org/10.1590/1678-775720160139.

10. Nitin K Upadhyay, Yogendra Kumar MS, Asheesh Gupta. (2010). Antioxidant, cytoprotective and antibacterial effects of Sea buckthorn (Hippophae rhamnoides L.) leaves. Food and Chemical Toxicology. 48: 3443—3448. https://doi.org/10.1016/j.fct.2010.09.019.

11. Qadir Muhammad Imran, Khizar A, Adnan Y, Rehan SS. (2016, Sept). Activity of sea buckthorn (Hippophae rhamnoides L.) against methicillin resistant Staphylococcus aureus (MRSA). Pak J Pharm Sci. 29; 5: 1711—1713. PMid:27731833

12. Rafalska A, Abramowicz K, Krauze M. (2017). Sea buckthorn (Hippophae rhamnoides L.) as a plant for universal application. World Scientific News. 72: 123—140.

13. Sore throat (acute): antimicrobial prescribing NICE guideline. Published: 26 January 2018. 25р. https://www.nice.org.uk/terms-and-conditions-notice-of-rights.

14. Stelter K. (2014). Tonsillitis and sore throat in children. GMS Current Topics in Otorhinolaryngology. Head and Neck Surgery. 13. https://www.researchgate.net/publication/307757733_Tonsillitis_and_sore_throat_in_children. PMid:25587367 PMCid:PMC4273168

15. Tatochenko V, Cherkasova E, Kuznetsova T. (2018, Sept.). Acute Tonsillitis and Bronchitis in Russian Primary Pediatric Care: Prevailing Antibacterial Treatment Tactics and Their Optimization. American Journal of Pediatrics. 4; 3: 46—51. https://doi.org/10.11648/j.ajp.20180403.11

16. Udayan K Shah. Tonsillitis and Peritonsillar Abscess Guidelines. Drugs & Diseases — Otolaryngology and Facial Plastic Surgery. Updated: Mar 19, 2018 https://emedicine.medscape.com/article/871977-overview.

Article received: Sep 28, 2018. Accepted for publication: Jan 29, 2019.